Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
1397966 | European Journal of Medicinal Chemistry | 2009 | 10 Pages |
In the present study, on the development of new anticonvulsants, the series of N-[(4-arylpiperazin-1-yl)-alkyl]-3-(2-methylphenyl)- (8a–e, 10a–h) and 3-(2-trifluoromethyl-phenyl)-pyrrolidine-2,5-diones (9a–e, 11a–i) were synthesized and tested for anticonvulsant activity using the maximal electroshock (MES), subcutaneous pentylenetetrazole (scPTZ) screens. Their neurotoxicity were determined applying the rotorod test. In this series, the most active were N-[(4-phenylpiperazin-1-yl)-methyl]-3-(2-trifluoromethylphenyl)-pyrrolidine-2,5-dione (9a) with the ED50 = 20.78 mg/kg, when given orally to rats and N-[3-{4-(3-trifluoromethylphenyl)-piperazin-1-yl}-propyl]-3-(2-trifluoromethylphenyl)-pyrrolidine-2,5-dione (11i) with the ED50 = 132.13 mg/kg after intraperitoneally injection to mice.
Graphical abstractA new series of N-[(4-arylpiperazin-1-yl)-alkyl]-3-phenyl-pyrrolidine-2,5-diones were synthesized. Majority of these compounds were effective in the MES test.Figure optionsDownload full-size imageDownload as PowerPoint slide